Condition

Malignant Neoplasm of Prostate

ClinicalTrials.gov condition label

Clinical trials8

Recruiting2

Common interventions17

Lead sponsors shown5

Clinical trials

8 shown

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate CancerNCT06574880 · 2025-05-13

MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)NCT06150417 · 2024-07-01

68Ga-AAZTA-093 PET/CT: First-in-human StudyNCT06437496 · 2024-04-01

Exercise Therapy and Radiation Therapy (EXERT) for Metastatic Prostate CancerNCT04556045 · 2023-12-11

Single-Port Versus Multi-Port Robotic Radical ProstatectomyNCT04696263 · 2022-09-01

Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic DiseaseNCT04765423 · 2021-03-25

Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized TrialNCT04534075 · 2020-09-02

Hypofractionated Radiation Therapy in Prostate CancerNCT01764646 · 2012-09-01

Common interventions

[F-18] fluciclovine PET/CTDEVICE1 [F-18] NaF PET/CTDEVICE1 5-fraction Stereotactic Body Radiation Therapy (SBRT)RADIATION1 68Ga-AAZTA-093DRUG1 68Ga-PSMA-11//68Ga-PSMA-617DRUG1 Androgen deprivation therapy (ADT)DRUG1 Androgen receptor signaling inhibitor (ARSI)DRUG1 Capsules containing either dietary fiber or placeboBIOLOGICAL1 Da Vinci ® SP system - SP Robotic Radical ProstatectomyDEVICE1 Da Vinci ® Xi system - MP Robotic Radical ProstatectomyDEVICE1 Exercise therapyBEHAVIORAL1 Image guided radiation therapyRADIATION1 Intensity modulated radiation therapyRADIATION1 Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)OTHER1 Lu-PSMA-617DRUG1 Metastasis directed radiotherapy (MDRT)RADIATION1 Volumetric modulated arc therapyRADIATION1

Leading sponsors

Case Comprehensive Cancer Center4 Angela Y. Jia, MD PhD1 First Affiliated Hospital of Fujian Medical University1 Sahlgrenska University Hospital1 Thomas Zilli1

Trial status mix

COMPLETED2

RECRUITING2

UNKNOWN2

WITHDRAWN2

Phase mix

NA4

PHASE22

EARLY_PHASE11

PHASE11

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.